Welcome to our dedicated page for Adicet Bio SEC filings (Ticker: ACET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adicet Bio, Inc. filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies. Its Form 8-K reports cover material events, financial results, clinical and regulatory updates for prula-cel and ADI-212, Nasdaq listing-rule matters, and capital-structure disclosures involving common stock and pre-funded warrants.
Proxy filings describe shareholder voting matters, board and governance procedures, executive compensation, equity-award disclosures, and proposals affecting the company’s certificate of incorporation and share structure. These documents connect Adicet’s cell-therapy pipeline with its public-company governance, equity compensation, and financing-related disclosure obligations.
Adicet Bio, Inc. filed an amended annual report to update its disclosure on controls and procedures for the year ended December 31, 2025. The company explains that its original Form 10-K omitted required statements about the effectiveness and design of its disclosure controls and procedures.
Management, including the CEO and CFO, evaluated these disclosure controls and concluded they were effective as of December 31, 2025 and are designed to provide reasonable assurance that required information is properly recorded and reported. They also concluded that internal control over financial reporting was effective at the reasonable assurance level as of the same date, based on the COSO framework, without an auditor attestation because Adicet Bio is a non-accelerated filer.
The amendment does not change the company’s financial statements or other disclosures, and it states that the filing is not an admission that the original report contained any material misstatement or omission. As of June 30, 2025, non-affiliate common stock had an aggregate market value of about $50.5 million, and as of May 19, 2026, there were 9,348,236 common shares outstanding.
Adicet Bio reported a Schedule 13G/A amendment showing that Woodline Partners beneficially owns 313,124 shares of common stock, representing 3.3% of the class. The filing cites March 10, 2026 as the outstanding-share anchor of 9,596,407 shares.
The statement lists sole voting and dispositive power over the 313,124 shares by the Woodline Fund. The filing is a passive ownership disclosure filed under the ownership threshold rules rather than an active acquisition or disposition report.
Adicet Bio reported a net loss of $20.2 million for the quarter ended March 31, 2026, narrowing from $28.2 million a year earlier as it reduced operating expenses. Research and development spending fell 23% to $17.5 million, and general and administrative costs declined 42% to $4.1 million, largely from lower headcount and stock-based compensation.
Total assets were $169.4 million, including $36.2 million in cash and cash equivalents and $101.3 million in short-term U.S. Treasury securities, against total liabilities of $29.3 million. Management expects existing cash, cash equivalents and short-term investments to fund operations for at least twelve months.
Adicet continues to focus on prula-cel, its lead allogeneic gamma delta CAR-T candidate for autoimmune diseases, with ongoing Phase 1 trials in lupus nephritis, systemic lupus erythematosus, systemic sclerosis and other indications, and on ADI-212 for metastatic castration-resistant prostate cancer, for which it plans a regulatory filing in the third quarter of 2026.
Adicet Bio reported first quarter 2026 results and highlighted progress across its allogeneic gamma delta T cell pipeline. Net loss narrowed to $20.2 million, or $1.88 per share, from $28.2 million a year earlier, driven by lower research and development and general and administrative costs.
R&D expenses fell to $17.5 million from $22.8 million, while G&A declined to $4.1 million from $7.1 million. Cash, cash equivalents and short-term investments were $137.6 million as of March 31, 2026, which the company expects will fund operations into the second half of 2027.
Adicet plans a mid‑2026 clinical update from its Phase 1 autoimmune trial of prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus, with at least 20 patients and six months’ follow-up. A regulatory interaction to inform potential pivotal trial design is expected in the second quarter of 2026, and a regulatory filing for ADI‑212 in metastatic castration-resistant prostate cancer is planned for the third quarter of 2026.
Adicet Bio, Inc. reported that an affiliate of RA Capital restructured part of its position through an exchange. On April 27, 2026, RA Capital Healthcare Fund, L.P. entered into an Exchange Agreement to swap 250,000 shares of Adicet Bio common stock for a pre-funded warrant for up to 250,000 common shares at an exercise price of $0.0001 per share, for no additional consideration. Following the transactions, the Fund held 932,624 shares of common stock and 1,402,833 pre-funded warrant shares indirectly. The pre-funded warrant is exercisable immediately, has no expiration date, and includes a 9.99% beneficial ownership limit that prevents exercises above that level when combined with Attribution Parties.
Adicet Bio, Inc. is holding its 2026 annual stockholders meeting virtually on June 17, 2026 at 5:00 p.m. Eastern Time. Holders of common stock as of April 21, 2026, when 9,598,201 shares were outstanding, may vote online, by phone, mail or during the webcast using a 16‑digit control number.
Stockholders will vote on electing three Class II directors to terms ending in 2029, approving on a non‑binding advisory basis the compensation of named executive officers, and ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026. The proxy describes board structure, committee responsibilities, director and executive biographies, and outlines the company’s executive and director compensation programs, including cash retainers, equity awards, and 2025 bonus opportunities.
Adicet Bio, Inc. entered into an exchange agreement with RA Capital under which RA Capital swapped 250,000 shares of Adicet common stock for a pre-funded warrant to acquire 250,000 common shares.
The warrant carries a token exercise price of $0.0001 per share and is exercisable immediately via cashless exercise. It includes a 9.99% cap on both beneficial ownership and voting power, which can be increased on at least 61 days’ prior notice but not above 19.99%. The issuance relied on the Section 3(a)(9) exemption from Securities Act registration.
RA Capital Management, L.P. and affiliated reporting persons reported beneficial ownership of 1,182,624 shares of Adicet Bio, Inc. common stock. The filing states the Fund also holds pre-funded warrants exercisable for up to 1,152,833 additional shares, but a Beneficial Ownership Blocker prevents exercise that would raise ownership above 9.99%. The percentage reported (12.3%) is calculated using 9,596,407 shares outstanding as of March 10, 2026. The filing discloses delegated voting and dispositive authority to RA Capital and includes standard disclaimers regarding beneficial ownership for Section 13(d) purposes.
RA Capital–affiliated entities reported open-market purchases of Adicet Bio common stock. RA Capital Healthcare Fund LP, managed by RA Capital Management, L.P., bought 74,577 shares at $7.04 on February 18, 74,268 shares at $7.21 on February 19, and 74,751 shares at $7.27 on February 20. All shares are held directly by the Fund, with RA Capital and individuals Peter Kolchinsky and Rajeev Shah disclaiming beneficial ownership beyond their pecuniary interests. After the latest trade, the indirect holdings reported for the Fund total 1,182,624 shares, and no derivative securities are listed.